Home > Insider Trading > Filing (0000899243-21-027891)

Filing Details

Accession Number:: 0000899243-21-027891
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-07-08 17:21:31
Reporting Period:: 2021-07-06

Accepted Time:: 2021-07-08 17:21:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1576885	Acumen Pharmaceuticals Inc.	ABOS	Biological Products, (No Disgnostic Substances) (2836)	364108129

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1870490	Sands Capital Life Sciences Pulse Fund, Llc	1000 Wilson Blvd, Suite 3000 Arlington VA 22209	No	No	Yes	No
1870491	Sands Capital Ventures Discovery Fund Iii, L.p.	1000 Wilson Blvd., Suite 3000 Arlington VA 22209	No	No	Yes	No
1870493	Sands Capital Global Venture Fund Ii, L.p.	1000 Wilson Blvd, Suite 3000 Arlington VA 22209	No	No	Yes	No
1870494	M. Frank Sands	1000 Wilson Blvd, Suite 3000 Arlington VA 22209	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-07-06	1,124,729	$0.00	1,124,729	No	4	C	Direct
Common Stock	Acquisiton	2021-07-06	1,842,346	$0.00	2,967,075	No	4	C	Direct
Common Stock	Acquisiton	2021-07-06	450,000	$14.88	3,417,075	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2021-07-06	1,124,729	$0.00	1,124,729	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-07-06	1,842,346	$0.00	1,842,346	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering.
Represents 225,000 shares of Common Stock acquired by Sands Capital Global Venture Fund II, L.P. ("Sands Venture Fund") and 225,000 shares of Common Stock acquired by ands Capital Life Sciences Pulse Fund ("Sands Pulse Fund") in connection with the closing of the Issuer's initial public offering.
Consists of 1,124,719 shares of Common Stock held by Sands Capital Ventures Discovery Fund III, L.P. ("Sands Discovery Fund "). Sands Capital Ventures Discovery Fund III-GP, LLC ("Sands Discovery GP") is the general partner of Sands Discovery Fund. Sands Discovery GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Consists of 921,173 shares of Common Stock held by Sands Venture Fund and 921,173 shares of Common Stock held by Sands Pulse Fund. Sands Capital Global Venture Fund II-GP, L.P. ("Sands Venture GP L.P.") is the general partner of Sands Venture Fund and Sands Capital Global Venture Discovery Fund II-GP, LLC ("Sands Venture GP LLC") is the general partner of Sands Venture GP L.P. Sands Venture GP L.P. and Sands Venture GP LLC each disclaims beneficial ownership of such securities except to the extent of its respective pecuniary interest therein.
Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.